The third national Japanese antimicrobial susceptibility pattern surveillance program: Bacterial isolates from complicated urinary tract infection patients.

Adult Aged Aged, 80 and over Anti-Bacterial Agents / therapeutic use Bacteria / drug effects Bacterial Infections / drug therapy Drug Resistance, Bacterial / drug effects Enterococcus faecalis / drug effects Escherichia coli / drug effects Female Fluoroquinolones / therapeutic use Humans Japan / epidemiology Klebsiella pneumoniae / drug effects Levofloxacin / pharmacology Male Methicillin-Resistant Staphylococcus aureus / drug effects Microbial Sensitivity Tests / methods Middle Aged Proteus mirabilis / drug effects Pseudomonas aeruginosa / drug effects Urinary Tract Infections / drug therapy Vancomycin / therapeutic use Young Adult
Antimicrobial susceptibility Complicated urinary tract infection Minimum inhibitory concentration Surveillance

Journal

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
ISSN: 1437-7780
Titre abrégé: J Infect Chemother
Pays: Netherlands
ID NLM: 9608375

Informations de publication

Date de publication:
May 2020
Historique:
received: 13 11 2019
revised: 08 01 2020
accepted: 21 01 2020
pubmed: 23 2 2020
medline: 11 11 2020
entrez: 22 2 2020
Statut: ppublish

Résumé

The antimicrobial susceptibility patterns of bacterial pathogens isolated from patients with complicated urinary tract infections were analyzed using national surveillance data. The data consisted of 881 bacterial strains from eight clinically relevant species. The data were collected for the third national surveillance project from January 2015 to March 2016 by the Japanese Society of Chemotherapy, the Japanese Association for Infectious Disease, and the Japanese Society of Clinical Microbiology. Surveillance was undertaken with the cooperation of 41 medical institutions throughout Japan. Fluoroquinolone required a MIC

Identifiants

DOI: 10.1016/j.jiac.2020.01.004 PMID: 32081647
pubmed: 32081647
pii: S1341-321X(20)30018-0
doi: 10.1016/j.jiac.2020.01.004
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Fluoroquinolones 0
Levofloxacin 6GNT3Y5LMF
Vancomycin 6Q205EH1VU

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

418-428

Informations de copyright

Copyright © 2020 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest Shingo Yamamoto has received speaker's honorarium from Daiichi Sankyo Co., Ltd., and scholarship donations from Astellas Pharma Inc., Takeda Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd, Pfizer Japan Inc., and Bayer Yakuhin, Ltd. Satoshi Takahashi has received speaker honoraria from Daiichi Sankyo Co., Ltd. and MSD K.K., and research grants from Shino-Test Corporation and Abbott Japan Co., Ltd. Ryoichi Hamasuna has received speaker's honorarium from Daiichi Sankyo Co. Ltd. Shinichiro Minamitani is an employee of Daiichi Sankyo Co., Ltd. Tetsuya Matsumoto has received speaker's honorarium from MSD K.K. and Pfizer Japan Inc. Hiroshi Kiyota and Hiroki Yamada have received scholarship donations from Taisho Toyama Pharmaceutical Co., Ltd., Toyama Chemical Co., Ltd., Daiichi Sankyo Co., Ltd., Astellas Pharma Inc., Taiho Pharmaceutical Co., Ltd., and Sanofi K.K. Kazuhiro Tateda received speaker honoraria from Pfizer Japan Inc., MSD K.K., Sumitomo Dainippon Pharma Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd. and Meiji Seika Pharma Co., Ltd., research funding from Meiji Seika Pharma Co., Ltd., Nippon Becton Dickinson Company, Ltd., Asahi Kasei Pharma Corporation, Eidia Co., Ltd., Eiken Chemical Co. Ltd., Nissui Pharmaceutical Co., Ltd., Spero OpCo, Inc., Shimadzu Corporation, Hitachi Ltd., Kyorin Pharmaceutical Co., Ltd., MSD K.K., Denka Company Limited, KD-ICONS Co. Ltd., and grant support from Taisho Toyama Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Asahi Kasei Pharma Corporation, Shionogi & Co., Ltd., Meiji Seika Pharma Co., Ltd., Daiichi Sankyo Co., Ltd., Pfizer Japan Inc., Astellas Pharma Inc., and FUJIFILM Toyama Chemical Co., Ltd., and scholarship donations from Taisho Toyama Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Asahi Kasei Pharma Corporation, Shionogi & Co., Ltd., Meiji Seika Pharma Co., Ltd., Daiichi Sankyo Co., Ltd., Pfizer Japan Inc., Astellas Pharma Inc. and FUJIFILM Toyama Chemical Co., Ltd., and has an endowed department sponsored by Meiji Seika Pharma Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Astellas Pharma Inc., Taisho Toyama Pharmaceutical Co., Ltd., MSD K.K. and Daiichi Sankyo Co., Ltd. Hiroyuki Nishiyama has received speaker's honorarium from MSD K.K., AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd. and Astellas Pharma Inc., research funding from Astellas Pharma Inc., Ono Pharmaceutical Co., Ltd. and Chugai Pharmaceutical Co., Ltd., and scholarship donations from Astellas Pharma Inc., Novartis Pharma K.K., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd. and Ono Pharmaceutical Co., Ltd.

Auteurs

Kanao Kobayashi (K)

Urogenital Sub-Committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, Japan Organization of Occupational Health and Safety, Chugoku Rosai Hospital, Hiroshima, Japan. Electronic address: kanaosandy@yahoo.co.jp.

Shingo Yamamoto (S)

Urogenital Sub-Committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, Hyogo College of Medicine Hospital, Hyogo, Japan.

Satoshi Takahashi (S)

Urogenital Sub-Committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Infection Control and Laboratory Medicine, Sapporo Medical University School of Medicine, Hokkaido, Japan.

Kiyohito Ishikawa (K)

Urogenital Sub-Committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, Fujita Health University Hospital, Aichi, Japan.

Mitsuru Yasuda (M)

Urogenital Sub-Committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, Graduate School of Medicine, Gifu University, Gifu, Japan.

Koichiro Wada (K)

Urogenital Sub-Committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

Ryoichi Hamasuna (R)

Urogenital Sub-Committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, The University of Occupational and Environmental Health Japan, Fukuoka, Japan.

Hiroshi Hayami (H)

Urogenital Sub-Committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Blood Purification Center, Kagoshima University Hospital, Kagoshima, Japan.

Shinichi Minamitani (S)

The Surveillance Committee of JSC, JAID and JSCM, Tokyo, Japan; Daiichi Sankyo Co., Ltd, Japan.

Tetsuya Matsumoto (T)

The Surveillance Committee of JSC, JAID and JSCM, Tokyo, Japan.

Hiroshi Kiyota (H)

The Surveillance Committee of JSC, JAID and JSCM, Tokyo, Japan; Department of Urology, The Jikei University Katsushika Medical Center, Tokyo, Japan.

Kazuhiro Tateda (K)

The Surveillance Committee of JSC, JAID and JSCM, Tokyo, Japan.

Junko Sato (J)

The Surveillance Committee of JSC, JAID and JSCM, Tokyo, Japan.

Hideaki Hanaki (H)

Infection Control Research Center, Kitasato University, Tokyo, Japan.

Naoya Masumori (N)

Department of Urology, Sapporo Medical University School of Medicine, Hokkaido, Japan.

Yoshiki Hiyama (Y)

Department of Urology, Sapporo Medical University School of Medicine, Hokkaido, Japan.

Hiroki Yamada (H)

Department of Urology, The Jikei University Katsushika Medical Center, Tokyo, Japan.

Shin Egawa (S)

Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.

Takahiro Kimura (T)

Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.

Hiroyuki Nishiyama (H)

Department of Urology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.

Jun Miyazaki (J)

Department of Urology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.

Kazumasa Matsumoto (K)

Department of Urology, Kitasato University School of Medicine, Kanagawa, Japan.

Yukio Homma (Y)

Department of Urology, The University of Tokyo Hospital, Tokyo, Japan.

Jun Kamei (J)

Department of Urology, The University of Tokyo Hospital, Tokyo, Japan.

Kiyohide Fujimoto (K)

Department of Urology, Nara Medical University, Kashihara, Japan.

Kazumasa Torimoto (K)

Department of Urology, Nara Medical University, Kashihara, Japan.

Kazushi Tanaka (K)

Division of Urology, Kobe University Graduate School of Medicine, Hyogo, Japan.

Yoshikazu Togo (Y)

Department of Urology, Hyogo College of Medicine Hospital, Hyogo, Japan.

Shinya Uehara (S)

Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

Akio Matsubara (A)

Department of Urology, Graduate School of Biomedical and Health Sciences Hiroshima University, Hiroshima, Japan.

Koichi Shoji (K)

Department of Urology, Graduate School of Biomedical and Health Sciences Hiroshima University, Hiroshima, Japan.

Hirokazu Goto (H)

Department of Urology, Fuji City General Hospital, Shizuoka, Japan.

Hisao Komeda (H)

Department of Urology, Gifu Municipal Hospital, Gifu, Japan.

Toru Ito (T)

Department of Urology, Nagoya Ekisaikai Hospital, Aichi, Japan.

Katsuhisa Mori (K)

Department of Urology, Kobayashi City Hospital, Miyazaki, Japan.

Koji Mita (K)

Department of Urology, Hiroshima City Asa Citizens Hospital, Hiroshima, Japan.

Masao Kato (M)

Department of Urology, Hiroshima City Asa Citizens Hospital, Hiroshima, Japan.

Yoshinori Fujimoto (Y)

Department of Urology, Ogaki Municipal Hospital, Gifu, Japan.

Takako Masue (T)

Department of Urology, Ogaki Municipal Hospital, Gifu, Japan.

Hisato Inatomi (H)

Department of Urology, Munakata Suikokai General Hospital, Fukuoka, Japan.

Yoshito Takahashi (Y)

Department of Urology, Gifu Prefectural General Medical Center, Gifu, Japan.

Satoshi Ishihara (S)

Department of Urology, Kizawa Memorial Hospital, Gifu, Japan.

Kazuo Nishimura (K)

Department of Urology, Osaka Red Cross Hospital, Osaka, Japan.

Kenji Mitsumori (K)

Department of Urology, Osaka Red Cross Hospital, Osaka, Japan.

Noriyuki Ito (N)

Department of Urology, Kobe City Nishi-Kobe Medical Center, Hyogo, Japan.

Sojun Kanamaru (S)

Department of Urology, Kobe City Nishi-Kobe Medical Center, Hyogo, Japan.

Daisuke Yamada (D)

Department of Urology, Mitoyo General Hospital, Kagawa, Japan.

Maeda Hiroshi (M)

Department of Urology, Yodogawa Christian Hospital, Osaka, Japan.

Masuo Yamashita (M)

Department of Urology, Shinko Hospital, Hyogo, Japan.

Masaya Tsugawa (M)

Department of Urology, Okayama City Hospital, Okayama, Japan.

Tadasu Takenaka (T)

Department of Urology, Red Cross Okayama Hospital, Okayama, Japan.

Koichi Takahashi (K)

Department of Urology, Fukuoka Shin Mizumaki Hospital, Fukuoka, Japan.

Yasuhiko Oka (Y)

Department of Urology, Kakogawa Central City Hospital, Hyogo, Japan.

Tomihiko Yasufuku (T)

Department of Urology, Kakogawa Central City Hospital, Hyogo, Japan.

Shuji Watanabe (S)

Department of Urology, Saiseikai Chuwa Hospital, Nara, Japan.

Yoshitomo Chihara (Y)

Department of Urology, Saiseikai Chuwa Hospital, Nara, Japan.

Kazuhiro Okumura (K)

Department of Urology, Tenri Hospital, Nara, Japan.

Hiroaki Kawanishi (H)

Department of Urology, Tenri Hospital, Nara, Japan.

Masanori Matsukawa (M)

Department of Urology, Takikawa Municipal Hospital, Hokkaido, Japan.

Masanobu Shigeta (M)

Department of Urology, National Hospital Organization Kure Medical Center, Hiroshima, Japan.

Shuntaro Koda (S)

Department of Urology, National Hospital Organization Kure Medical Center, Hiroshima, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › The third national Japanese antimicrobial...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › The third national Japanese antimicrobial...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Sujet âgé de 80 ans ou plus › The third national Japanese antimicrobial...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antibactériens › The third national Japanese antimicrobial...
questionsmedicales.fr › Bactéries › The third national Japanese antimicrobial...
questionsmedicales.fr › Infection › Infections bactériennes et mycoses › Infections bactériennes › The third national Japanese antimicrobial...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Résistance microbienne aux médicaments › Résistance bactérienne aux médicaments › The third national Japanese antimicrobial...
questionsmedicales.fr › Bactéries › Bactéries à Gram positif › Lactobacillales › Enterococcaceae › Enterococcus › Enterococcus faecalis › The third national Japanese antimicrobial...
questionsmedicales.fr › Bactéries › Proteobacteria › Gammaproteobacteria › Enterobacteriaceae › Escherichia › Escherichia coli › The third national Japanese antimicrobial...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Quinoléines › Quinolinone › Fluoroquinolones › The third national Japanese antimicrobial...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › The third national Japanese antimicrobial...
questionsmedicales.fr › Régions géographiques › Iles › Japon › The third national Japanese antimicrobial...
questionsmedicales.fr › Bactéries › Proteobacteria › Gammaproteobacteria › Enterobacteriaceae › Klebsiella › Klebsiella pneumoniae › The third national Japanese antimicrobial...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Quinoléines › Quinolinone › Fluoroquinolones › Ofloxacine › Lévofloxacine › The third national Japanese antimicrobial...
questionsmedicales.fr › Bactéries › Bactéries à Gram positif › Cocci à Gram positif › Staphylococcaceae › Staphylococcus › Staphylococcus aureus › Staphylococcus aureus résistant à la méticilline › The third national Japanese antimicrobial...
questionsmedicales.fr › Techniques d'investigation › Évaluation préclinique de médicament › Tests de sensibilité microbienne › The third national Japanese antimicrobial...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › The third national Japanese antimicrobial...
questionsmedicales.fr › Bactéries › Proteobacteria › Gammaproteobacteria › Enterobacteriaceae › Proteus › Proteus mirabilis › The third national Japanese antimicrobial...
questionsmedicales.fr › Bactéries › Proteobacteria › Gammaproteobacteria › Pseudomonadaceae › Pseudomonas › Pseudomonas aeruginosa › The third national Japanese antimicrobial...
questionsmedicales.fr › Maladies urogénitales › Maladies urologiques › Infections urinaires › The third national Japanese antimicrobial...
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Glycopeptides › Vancomycine › The third national Japanese antimicrobial...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Jeune adulte › The third national Japanese antimicrobial...